Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity.

Bariatric surgery Cirugía bariátrica Esteatohepatitis no alcohólica Morbid obesity Non-alcoholic steatohepatitis Non-invasive predictors Obesidad mórbida Predictores no invasivos

Journal

Endocrinologia, diabetes y nutricion
ISSN: 2530-0180
Titre abrégé: Endocrinol Diabetes Nutr (Engl Ed)
Pays: Spain
ID NLM: 101717565

Informations de publication

Date de publication:
30 Jul 2021
Historique:
received: 21 12 2020
revised: 27 03 2021
accepted: 07 04 2021
entrez: 3 8 2021
pubmed: 4 8 2021
medline: 4 8 2021
Statut: aheadofprint

Résumé

Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in morbid obesity (MO). A considerable proportion of patients with MO have non-alcoholic steatohepatitis (NASH). Liver biopsy (LB) is the only procedure that reliably differentiates NASH from other stages of NAFLD, but its invasive nature prevents it from being generalisable. Hence, non-invasive assessment is critical in this group of patients. To report NAFLD/NASH prevalence in a cohort of patients with MO and to identify predictors of NASH. Fifty-two consecutive patients subjected to bariatric surgery in a University hospital in Spain underwent LB. Anthropometric, clinical and biochemical variables were registered. According of the results of the LB, individuals were classified by whether they had NASH or not. Multiple logistic regression analysis was performed to identify independent factors associated with NASH. NAFLD was reported in 94.2% of the patients, simple steatosis was present in 51.92% and NASH in 42.31%. Meanwhile, 17.3% of patients exhibited significant fibrosis (≥F2). HIGHT score for NASH risk was established using five independent predictors: systemic Hypertension, Insulin resistance, Gamma-glutamyl transferase, High density lipoprotein cholesterol and alanine Transaminase. This score ranges from 0 to 7 and was used to predict NASH in our cohort (area under the receiver operator characteristic curve 0.846). A score of 4 or greater implied high risk (sensitivity 77.3%, specificity 73.3%, positive predictive value 68%, negative predictive value 81.5%, accuracy 75%). NAFLD is practically a constant in MO with a considerable proportion of patients presenting NASH. The combination of five independent predictors in a scoring system may help the clinician optimise the selection of patients with MO for LB.

Sections du résumé

BACKGROUND BACKGROUND
Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in morbid obesity (MO). A considerable proportion of patients with MO have non-alcoholic steatohepatitis (NASH). Liver biopsy (LB) is the only procedure that reliably differentiates NASH from other stages of NAFLD, but its invasive nature prevents it from being generalisable. Hence, non-invasive assessment is critical in this group of patients.
OBJECTIVES OBJECTIVE
To report NAFLD/NASH prevalence in a cohort of patients with MO and to identify predictors of NASH.
METHODS METHODS
Fifty-two consecutive patients subjected to bariatric surgery in a University hospital in Spain underwent LB. Anthropometric, clinical and biochemical variables were registered. According of the results of the LB, individuals were classified by whether they had NASH or not. Multiple logistic regression analysis was performed to identify independent factors associated with NASH.
RESULTS RESULTS
NAFLD was reported in 94.2% of the patients, simple steatosis was present in 51.92% and NASH in 42.31%. Meanwhile, 17.3% of patients exhibited significant fibrosis (≥F2). HIGHT score for NASH risk was established using five independent predictors: systemic Hypertension, Insulin resistance, Gamma-glutamyl transferase, High density lipoprotein cholesterol and alanine Transaminase. This score ranges from 0 to 7 and was used to predict NASH in our cohort (area under the receiver operator characteristic curve 0.846). A score of 4 or greater implied high risk (sensitivity 77.3%, specificity 73.3%, positive predictive value 68%, negative predictive value 81.5%, accuracy 75%).
CONCLUSIONS CONCLUSIONS
NAFLD is practically a constant in MO with a considerable proportion of patients presenting NASH. The combination of five independent predictors in a scoring system may help the clinician optimise the selection of patients with MO for LB.

Identifiants

pubmed: 34340957
pii: S2530-0164(21)00180-4
doi: 10.1016/j.endinu.2021.04.007
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Informations de copyright

Copyright © 2021 SEEN y SED. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

Diego Meneses (D)

Obesity Unit, Department of Endocrinology and Metabolism, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain. Electronic address: samoth67@gmail.com.

Antonio Olveira (A)

Liver Unit, Department of Gastroenterology, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.

Ramón Corripio (R)

Metabolic Surgery Unit, Department of General Surgery, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.

María Del Carmen Méndez (MDC)

Department of Pathology, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.

Míriam Romero (M)

Liver Unit, Department of Gastroenterology, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.

Isabel Calvo-Viñuelas (I)

Obesity Unit, Department of Endocrinology and Metabolism, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.

Lucrecia Herranz (L)

Department of Endocrinology and Metabolism, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.

David Vicent (D)

Instituto de Investigación Sanitaria [Health Research Institute] of Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.

Ana Isabel de-Cos-Blanco (AI)

Obesity Unit, Department of Endocrinology and Metabolism, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.

Classifications MeSH